Trial Profile
A Phase II Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk MDS and AML With Del 5q
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Apr 2017
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Cytarabine; Daunorubicin
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- Acronyms GFM-Chimio-Rev
- 23 Apr 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Jun 2015 to 1 Dec 2015.
- 23 Apr 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Jun 2015 to 1 Dec 2015.
- 23 Apr 2015 According to the ClinicalTrials.gov record, planned primary completion date changed from 1 Jan 2015 to 1 Dec 2015.